[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cell-free-dna\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cell-free-dna":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,60,89,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100629184","pesticides-and-infertility-oxidative-stress-via-circulating-cell-free-dna-and-gutgenital-microbiome-signatures-in-women-with-endometriosis-100629184",false,"NCT07471373","Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut\u002FGenital Microbiome Signatures in Women With Endometriosis","PestiEndoMicro","Inclusion Criteria:\n\n* The \"case\" group will include:\n* All women aged 18 to 43, with confirmed endometriosis and endometriosis grade 3 or 4 as defined by the 1985 revised version of the American Society of Reproductive Medicine.\n* The \"control\" group will include:\n* All women aged between 18 and 43, whose infertility problem is proven male infertility and who do not have endometriosis identified by biological, genetic and clinical tests.\n* The following criteria will apply to both groups:\n* All women who have not received antibiotic treatment in the three months preceding inclusion and who are not participating in any pharmacological study.\n* All women who are covered under the national social security health insurance scheme.\n* All women who have signed a written informed consent form, thereby confirming their participation in the study after a period of free and informed reflection.\n\nExclusion Criteria:\n\n* All women aged 44 and over.\n* Women who are overweight, obese or anorexic.\n* Women taking antibiotics 3 months prior to inclusion, or participating in a drug study.\n* All women under anti-GnRH treatment, pregnant or suffering from a chronic inflammatory disease such as Crohn's disease, polycystic ovary syndrome, etc.\n* All women whose endometriosis has not been formally confirmed by the tests offered by the Reproductive Medicine and Biology Department, CECOS de Picardie, CHU Amiens-Picardie.\n* All patients under guardianship, curators or safeguard of justice.\n* All patients who have not signed the written consent confirming their participation in the study, after a period of free and informed reflection.\n* Any patient who withdraws her consent for participation in the study.",true,"FEMALE","18 Years","43 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.",[28,29,30,31,32,33,34,35,36,37],"Endometriosis","Infertility","Female Fertility","Cell Free DNA","Genital Microbiota","Vaginal Microbiota","Endometrial Microbiota","Pesticides","Gut Microbiota","Epigenetics",[28,29,39,40,41,42,43,44,45,46],"Female fertility","cell free DNA","genital microbiota","vaginal microbiota","endometrial microbiota","pesticides","gut microbiota","epigenetics","RECRUITING","2026-05-12",{"date":50,"type":51},"2026-05-15","ACTUAL",{"date":53,"type":51},"2026-02-27",{"date":55,"type":22},"2028-05",{"name":57,"class":58},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":59},"100630919","hpv-after-chemoradiotherapy-100630919","NCT07493928","HPV After chemoRadioTherapy","Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer","HART","Inclusion Criteria:\n\n* Patient indicated for primary RT for cervical cancer\n* FIGO stage IB - IVA\n* Signed informed consent\n* Age ≥ 18 years\n* Administration of RT with curative intent\n\nExclusion Criteria:\n\n* Clinical stage FIGO IA\n* Clinical stage FIGO IVB\n* History of radiotherapy in the pelvis\n* Hysterectomy performed before the start of radiotherapy (adjuvant RT)\n* History of HPV-associated malignancy in personal history\n* HIV or other significant immunodeficiency",{"count":69,"type":22},120,"OBSERVATIONAL","The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, while the role of HPV-based molecular monitoring remains insufficiently defined. The study plans to enroll 120 patients with FIGO stage IB-IVA cervical cancer treated with primary radiotherapy with curative intent. HPV detection will be performed using two complementary approaches: PCR-based detection of HPV DNA from a cervical swab and analysis of circulating HPV tumor DNA (ctDNA) in peripheral blood. Samples will be collected before treatment and during follow-up at 3, 12, and 24 months after completion of CRT. The primary objective is to determine the sensitivity of these methods for detecting disease recurrence during a two-year follow-up period. Secondary objectives include evaluation of HPV clearance after treatment, comparison of HPV genotypes before and after therapy in cases of persistence, and comparison of the diagnostic performance of cervical HPV testing and ctDNA detection. The study aims to generate evidence supporting the integration of HPV-based molecular monitoring into routine follow-up, potentially enabling earlier detection of recurrence and more individualized surveillance strategies for patients after CRT for cervical cancer.",[73,74,31,75],"Cervical Cancer Recurrent","Radiotherapy","HPV",[77,78,79],"cervical cancer","cfDNA","radiotherapy","2026-03-20",{"date":82,"type":51},"2026-03-25",{"date":84,"type":51},"2026-02-01",{"date":86,"type":22},"2030-02-01",{"name":88,"class":58},"General University Hospital, Prague",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100593468","a-multicenter-prospective-blood-collection-study-in-a-kidney-transplant-population-100593468","NCT07006831","A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population","Accept cfDNA","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Is 18 years of age or older at enrollment\n3. Had a kidney transplant prior to enrollment\n4. Is having an indication (for cause) biopsy as determined by clinician\n5. retrospective leftover samples are available from the kidney donor(s).\n\nExclusion Criteria:\n\n1. Is pregnant\n2. Had a blood transfusion within the past 4 weeks\n3. Had a transplant from an identical (monozygotic) twin\n4. Had transplants of multiple organs from the same donor (eg, kidney and liver transplant).\n5. Had transplants of more than 2 organs from different donors (eg, recipient of a third kidney transplant)\n6. Had a transplant of hematopoietic stem cells (eg, bone marrow) or tissue (eg, heart valve)","ALL",{"count":98,"type":22},400,"The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.",[101,102,103,104,105,106],"Kidney Disease","Kidney Transplant","Transplant Recipient","Renal Function","Cell-free DNA","NGS","2025-12-15",{"date":109,"type":51},"2025-12-17",{"date":111,"type":51},"2025-11-14",{"date":113,"type":22},"2027-03",{"name":115,"class":116},"Devyser Inc.","INDUSTRY",6,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":96,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100597609","validation-of-donor-derived-cell-free-dna-dd-cfdna-for-kidney-transplant-monitoring-100597609","NCT07060716","Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring","GraftAssureDx Study: Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring","Inclusion Criteria:\n\n1. Subject is 18 years of age or older\n2. At least 12 calendar days have elapsed since the subject received a kidney transplant.\n3. Subject has provided legally effective informed consent\n4. Subject agrees to comply with all study procedures\n\nExclusion Criteria:\n\n1. Kidney donor is an identical twin of the subject.\n2. The subject has another previously transplanted organ in situ.\n3. Subject has received a hematopoietic stem cell transplant.\n4. Subject has received a bone marrow graft.\n5. Subject has self-reported as pregnant.\n6. In the opinion of the investigator, the subject's participation in the study would pose a risk to data integrity or to the subject's safety and welfare.\n\nSample Inclusion Criteria:\n\n1\\. A graft biopsy is obtained within ±1 week of blood draw.\n\n* If blood draw is obtained after biopsy, blood draw should be taken at least 2 days after an uncomplicated biopsy procedure.\n\nSample Exclusion Criteria:\n\n1. Sample collected from someone that had an invasive graft biopsy ≤ 48 hours prior to blood draw.\n2. Sample collected from subject that received immunosuppressive treatment for biopsy-proven acute rejection ≤ 30 days prior to blood draw\n3. Sample collected from subject that received a blood transfusion ≤ 30 days prior to blood draw.\n4. Sample collected from a subject that provided another sample for the study within the past 7 days.",{"count":126,"type":22},125,"The goal of this observational study is to learn if the donor-derived cell-free DNA (dd-cfDNA) test can assess rejection in kidney transplant recipients. Participants will have blood and urine collected at their study visit.\n\nResearchers will compare results of the GraftAssureDx to rejection detected by standard-of-care graft biopsies.",[129,105],"Kidney Transplant Rejection","2025-11-18",{"date":132,"type":51},"2025-11-19",{"date":134,"type":51},"2025-09-08",{"date":136,"type":22},"2025-12",{"name":138,"class":116},"Insight Molecular Diagnostics",10]